- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02499354
Pilot Study: Randomized, Placebo-controlled Comparator Trial of IV vs Oral Iron Treatment of RLS With IDA. (IVOR-IDA)
Double-blind Comparator of Efficacy of Oral (Ferrous Sulfate) vs. Intravenous Iron (Ferumoxytol) for Treatment of the Restless Legs Syndrome (RLS) Occurring With Iron Deficient Anemia (IDA)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The restless legs syndrome (RLS) (also known as Willis Ekbom Disease) occurs in about 1/3rd of patients with iron deficiency anemia (IDA). Treatment correcting the IDA is expected to also be effective for reducing or eliminating the RLS with IDA. Two accepted treatments for IDA (oral ferrous sulfate, intravenous ferumoxytol) will be compared for efficacy and speed to response for treatment of RLS occurring with IDA (RLS-IDA). In this study 70 RLS-IDA patients will be randomly assigned 35 each to oral or IV iron treatment using double-blind procedures. Primary outcome with be determined at 6 weeks of treatment with a follow-up at 12 months after treatment. Non-responders at 6 weeks after treatment may, if they qualify, have an open-label IV iron treatment and they will be followed with the same evaluations used after the first set of IV iron treatments.
Both oral and IV iron are considered standard treatments for IDA. These same treatments also reduce RLS symptoms. The treatment doses are those accepted for treatment of RLS and also appropriate for treatment for RLS-IDA. Choosing doses equivalent to those for the treatment of RLS without IDA will allow a comparison with that literature. The investigators will therefore use for oral iron ferrous sulfate 325mg taken twice a day matching the dose used in the study of oral iron treatment for RLS without anemia. For IV iron investigators will use ferumoxytol, provided by the sponsor, two doses of 510 mg spaced 2 to 7 days apart. This is the FDA approved dose for treatment of IDA with end stage renal disease.
The study is a randomized, comparative open label study to evaluate effect size and time course of treatment response for RLS-IDA over 6 weeks with a 46-week follow-up extension. Two medications and placebos will be used, as described above, with equal random assignment to both groups.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21237
- Auerbach Hematology Oncology Assoc
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of RLS based on questionnaire and confirmed by Hopkins telephone Diagnostic Interview conducted by investigators or clinicians part of the study.
- Iron deficiency anemia defined as ID either ferritin <20 mcg/l, Tsat <19%, anemia Hgb <13 for both males and females.
- Willingness to use contraceptive to avoid pregnancy: Women have to be surgically sterile, post-menopausal, or use one of the following contraceptives during the whole study period and after the study has ended for at least 5 times plasma biological half-life of the investigational medicinal product: intrauterine devices or hormonal contraceptives (contraceptive pills, implants, transdermal patches, hormonal vaginal devices, or injections with prolonged release).
- Willingness to participate and signing the informed consent form.
Exclusion Criteria:
- Iron overload or disturbances in utilization of iron (e.g. haemochromatosis and haemosiderosis)
- Decompensated liver cirrhosis or active hepatitis (ALAT > 3 times upper limit of normal)
- Serum ferritin > 500 ng/mL or transferrin saturation >40%
- Active acute or chronic infections (assessed by clinical judgement that may be indicated by White Blood Cells (WBC) and C-Reactive Protein (CRP) when these are available)
- Rheumatoid arthritis with symptoms or signs of active inflammation
- Pregnant and nursing women
- History of multiple allergies
- Known hypersensitivity to parenteral or oral iron or any excipients in the drug products
- Previous IV iron treatment for RLS
- Other iron treatment or blood transfusion within 4 weeks prior to the screening or treatment visit
- Planned elective surgery during the study
- Current (past 4 weeks) use of drugs that treat RLS, e.g. opioids, alpha-2-delta anti-depressants, dopaminergics (dopamine promoters, dopamine antagonists/blockers)
- Any other medical condition that, in the opinion of Investigator, may cause the subject to be unsuitable for the completion og the study or place the subject at potential risk from being in the study, e.g. a malignancy, uncontrolled hypertension, unstable ischemic heart disease, or uncontrolled diabetes mellitus.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Oral Iron
Ferrous Sulfate 325mg (oral) tabs morning and evening
|
Oral iron, 325 mg tabs taken morning and evening
Other Names:
|
Active Comparator: IV Iron
Ferumoxytol intravenous (IV) 1020 mg - 2 vials of 510 mg (IV push, 2-3 mins) each given 2-7 days apart
|
IV iron, 2 vials of 510 mg given 2-7 days apart
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in the Restless Legs Syndrome Rating Scale
Time Frame: Baseline and at 6 weeks after treatment
|
Change in International Restless Legs Severity Scale (IRLS) score reflecting RLS severity on the scale of 0-40.
The higher the negative score the better the outcome
|
Baseline and at 6 weeks after treatment
|
Percentage of Participants With Improvement on Clinical Global Impression Scale
Time Frame: Six weeks
|
Seven questions ranging from Very Much Improved to Very Much Worse: Participant had to be at least Very Much Improved to be considered as having improved.
The CGI scale consisted of one question.
|
Six weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Adverse Events Judged Related or Possibly Related to Treatment.
Time Frame: Up to six weeks
|
Patient reported gastrointestinal or constitutional adverse events
|
Up to six weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Adverse Events Judged Related or Possibly Related to Treatment.
Time Frame: 6 weeks after treatment
|
Adverse events as a measure of safety and tolerability of treatment.
|
6 weeks after treatment
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Michael Auerbach, MD, Auerbach Hematology and Oncology Associates, PC
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Pathologic Processes
- Metabolic Diseases
- Nervous System Diseases
- Sleep Disorders, Intrinsic
- Dyssomnias
- Sleep Wake Disorders
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Disease
- Hematologic Diseases
- Anemia, Hypochromic
- Iron Metabolism Disorders
- Dyskinesias
- Psychomotor Disorders
- Parasomnias
- Syndrome
- Psychomotor Agitation
- Restless Legs Syndrome
- Anemia, Iron-Deficiency
- Anemia
- Iron Deficiencies
- Physiological Effects of Drugs
- Trace Elements
- Micronutrients
- Hematinics
- Pharmaceutical Solutions
- Parenteral Nutrition Solutions
- Ferrosoferric Oxide
- Iron
Other Study ID Numbers
- IVOR-IDA
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Restless Legs Syndrome
-
Walter Reed National Military Medical CenterWithdrawnEkbom Syndrome | Restless Legs Syndrome, | Restless Legs,United States
-
XenoPort, Inc.CompletedRestless Legs Syndrome (RLS)United States
-
GlaxoSmithKlineCompletedRestless Legs Syndrome | Restless Legs Syndrome (RLS)United States
-
Otsuka Pharmaceutical Co., Ltd.CompletedIdiopathic Restless Legs Syndrome
-
American Regent, Inc.CompletedRestless Legs Syndrome (RLS)United States
-
Astellas Pharma IncCompletedRestless Legs Syndrome (RLS)Japan
-
Otsuka Pharmaceutical Co., Ltd.CompletedIdiopathic Restless Legs SyndromeJapan
-
UCB PharmaCompletedIdiopathic Restless Legs SyndromeGermany
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedIdiopathic Restless Legs SyndromeUnited States, Spain, Finland, Italy, Germany, Sweden, Austria, Netherlands, United Kingdom
-
American Regent, Inc.CompletedRestless Legs Syndrome (RLS)
Clinical Trials on Ferrous sulfate
-
Universidade Federal FluminenseActive, not recruitingDysbiosis | Anemia of Chronic Kidney Disease | Chronic Renal Disease | Iron-Deficiency AnemiaBrazil
-
Swiss Federal Institute of TechnologyUniversity of Oxford; St. Luke's Medical CenterTerminatedIron-deficiencyPhilippines
-
National Cardiovascular Center Harapan Kita Hospital...CompletedHeart Failure, Systolic | Iron-deficiency Anemia
-
Iowa State UniversityCompletedIron-deficiency | Iron Deficiency Anemia | Iron Deficiency Anemia Treatment | Iron Deficiency Anaemia Due to Dietary CausesUnited States
-
Duzce UniversityCompletedIron Deficiency Anemia | Subclinical HypothyroidismTurkey
-
Instituto de Desarrollo e Investigaciones Pediátricas...UnknownIron-deficiency | AnemiaArgentina
-
Indiana UniversityCompletedAutosomal Dominant Hypophosphatemic RicketsUnited States
-
Swiss Federal Institute of TechnologyUniversity Hospital, Zürich; ETH ZurichCompletedAnemia | Iron Deficiency Anemia | Iron DeficiencySwitzerland
-
Solvotrin Innovations LtdActive, not recruitingIron-deficiency | Iron Deficiency Anemia | Heavy Menstrual Bleeding | Premenopause | Iron Adverse ReactionIreland
-
Medical Research CouncilKing's College LondonCompletedAbdominal Pain | Constipation | Diarrhea | Anemia | Heartburn | Side EffectUnited Kingdom